Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Laser Photonics, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Raises approximately $9.3 mil. in private placement of restricted common stock shares at $4.50 each to institutional and accredited investors. Pennsylvania Merchant Group served as placement agent. Net proceeds will support clinical trials and marketing of the firm's excimer laser treatment for psoriasis; initial testing is complete, and a 510(k) submission is planned. Funds also will go towards manufacturing expenses and working capital. The Carlsbad, California firm is also developing a transmyocardial revascularization application for its excimer laser technology through an alliance with Baxter. Phase II trials will begin later this year

You may also be interested in...



Laser Photonics

Acculase subsidiary anticipates U.S. launch of its excimer laser system for the treatment of dermatological disorders including psoriasis in early 2000 following submission of a 510(k) to FDA on Aug. 31 (1"The Gray Sheet" Aug. 30, p. 23)

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel